相似文献
1
Heterogeneous, longitudinally stable molecular signatures in response to interferon-beta.
Ann N Y Acad Sci. 2009 Dec;1182:58-68. doi: 10.1111/j.1749-6632.2009.05068.x.
2
Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis.
PLoS One. 2011;6(5):e19262. doi: 10.1371/journal.pone.0019262. Epub 2011 May 13.
3
Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood.
Mol Neurobiol. 2013 Dec;48(3):737-56. doi: 10.1007/s12035-013-8463-1. Epub 2013 May 1.
4
Novel interferon-beta-induced gene expression in peripheral blood cells.
J Leukoc Biol. 2007 Nov;82(5):1353-60. doi: 10.1189/jlb.0507273. Epub 2007 Aug 20.
5
Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis.
J Neuroimmunol. 2003 Jun;139(1-2):109-18. doi: 10.1016/s0165-5728(03)00155-3.
6
Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.
Arch Neurol. 2008 Mar;65(3):337-44. doi: 10.1001/archneurol.2008.47. Epub 2008 Jan 14.
7
Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1.
J Neuroimmunol. 2002 Aug;129(1-2):205-15. doi: 10.1016/s0165-5728(02)00182-0.
8
Interferon-β inhibits toll-like receptor 9 processing in multiple sclerosis.
Ann Neurol. 2010 Dec;68(6):899-906. doi: 10.1002/ana.22136.
9
Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation.
Eur J Neurol. 2009 Dec;16(12):1291-8. doi: 10.1111/j.1468-1331.2009.02716.x. Epub 2009 Jun 22.
10
Differential gene expression and translational approaches to identify biomarkers of interferon beta activity in multiple sclerosis.
J Interferon Cytokine Res. 2010 Oct;30(10):743-9. doi: 10.1089/jir.2010.0022.
引用本文的文献
1
Early Transcriptional Responses After Dengue Vaccination Mirror the Response to Natural Infection and Predict Neutralizing Antibody Titers.
J Infect Dis. 2018 Nov 5;218(12):1911-1921. doi: 10.1093/infdis/jiy434.
2
Monocyte NOTCH2 expression predicts IFN-β immunogenicity in multiple sclerosis patients.
JCI Insight. 2018 Jun 7;3(11). doi: 10.1172/jci.insight.99274.
3
Janus-like effects of type I interferon in autoimmune diseases.
Immunol Rev. 2012 Jul;248(1):23-35. doi: 10.1111/j.1600-065X.2012.01131.x.
4
Type I interferons: beneficial in Th1 and detrimental in Th17 autoimmunity.
Clin Rev Allergy Immunol. 2013 Apr;44(2):114-20. doi: 10.1007/s12016-011-8296-5.
5
The role of cell type-specific responses in IFN-β therapy of multiple sclerosis.
Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19689-94. doi: 10.1073/pnas.1117347108. Epub 2011 Nov 21.
6
Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis.
PLoS One. 2011;6(5):e19262. doi: 10.1371/journal.pone.0019262. Epub 2011 May 13.
7
Gene regulatory and clinical effects of interferon β in patients with metastatic melanoma: a phase II trial.
J Interferon Cytokine Res. 2011 May;31(5):433-40. doi: 10.1089/jir.2010.0054. Epub 2011 Jan 15.
8
An overview of cytokines and cytokine antagonists as therapeutic agents.
Ann N Y Acad Sci. 2009 Dec;1182:1-13. doi: 10.1111/j.1749-6632.2009.05382.x.
本文引用的文献
1
IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression.
J Interferon Cytokine Res. 2008 May;28(5):317-31. doi: 10.1089/jir.2007.0131.
2
Interferons at age 50: past, current and future impact on biomedicine.
Nat Rev Drug Discov. 2007 Dec;6(12):975-90. doi: 10.1038/nrd2422.
3
MS therapy research applying genome-wide RNA profiling of peripheral blood.
Int MS J. 2007 Sep;14(3):98-107.
4
Novel interferon-beta-induced gene expression in peripheral blood cells.
J Leukoc Biol. 2007 Nov;82(5):1353-60. doi: 10.1189/jlb.0507273. Epub 2007 Aug 20.
5
Differential responses of normal human coronary artery endothelial cells against multiple cytokines comparatively assessed by gene expression profiles.
FEBS Lett. 2006 Dec 22;580(30):6871-9. doi: 10.1016/j.febslet.2006.11.041. Epub 2006 Nov 27.
6
Peripheral blood gene expression signature mirrors central nervous system disease: the model of multiple sclerosis.
Autoimmun Rev. 2006 Oct;5(8):517-22. doi: 10.1016/j.autrev.2006.02.009. Epub 2006 Mar 23.
7
Drug Insight: interferon treatment in multiple sclerosis.
Nat Clin Pract Neurol. 2006 Jan;2(1):34-44. doi: 10.1038/ncpneuro0088.
8
Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies.
J Neuroimmunol. 2006 Jul;176(1-2):125-33. doi: 10.1016/j.jneuroim.2006.03.019. Epub 2006 May 15.
9
Differential responses to IFN-alpha subtypes in human T cells and dendritic cells.
J Immunol. 2003 Nov 15;171(10):5255-63. doi: 10.4049/jimmunol.171.10.5255.
10
Genomic effects of IFN-beta in multiple sclerosis patients.
J Immunol. 2003 Sep 1;171(5):2694-702. doi: 10.4049/jimmunol.171.5.2694.
Zotero 插件